New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...
Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...
US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).
GlobalData on MSN23h
Amgen’s gMG therapy cuts disease symptoms at one-year markResults from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...
Antibody-drug conjugate (ADC) specialist Sutro Biopharma has shelved its lead drug for ovarian cancer and turned its ...
According to the latest study from BCC Research, "Technical Textiles: Global Markets," is expected to grow from $213.8 billion in 2024 to $284.0 billion by the end of 2029, at a compound annual growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback